Tarsgen

🧬 Biotech. 💊 Pharma. 🤖 AI.
News, deals & breakthroughs shaping life sciences.

[Tarsgen @Tarsgen]

🔄 Novo Nordisk is rebranding its everyday identity to “Novo” as CEO Mike Doustdar signals a broader strategic reset.

The company says diabetes and obesity will remain at the core of its business.

#NovoNordisk #Biotech #Pharma

[Tarsgen @Tarsgen]

🫘 Vera Therapeutics’ Trutakna delivered strong final Phase 3 results in IgA nephropathy.

At 104 weeks, the treatment reduced the risk of kidney disease progression events by 76% versus placebo while preserving kidney function.

#Biotech #IgAN #ClinicalTrials

[Tarsgen @Tarsgen]

🧬 AstraZeneca’s Etcamah missed the primary endpoint in the Phase 3 SERENA-4 breast cancer trial.

The combination failed to show a statistically significant progression-free survival benefit over the comparator treatment.

#Biotech #BreastCancer #AstraZeneca

[Tarsgen @Tarsgen]

🧬 The FDA has approved Scholar Rock’s Isembyld, the first SMA therapy designed to directly target muscle.

The myostatin inhibitor is used alongside existing SMN-targeted treatments to improve motor function.

#Biotech #SMA #FDA

[Tarsgen @Tarsgen]

🫀 FDA has authorized Powerful Medical’s Queen of Hearts AI-ECG model to help clinicians identify STEMI and STEMI-equivalent patterns linked to acute heart attacks.

The system analyzes standard 12-lead ECGs to flag patients who may need urgent evaluation.

#AI #MedTech #FDA

[Tarsgen @Tarsgen]

🫁 Bayer’s Hyrnuo has secured expanded FDA accelerated approval, bringing the HER2-targeted therapy into first-line treatment for previously untreated patients with HER2-mutant advanced NSCLC.

#Biotech #Bayer #FDA

[Tarsgen @Tarsgen]

🧬 Another Phase 3 setback for Novartis.

Del-desiran failed the primary endpoint of the pivotal HARBOR trial in myotonic dystrophy type 1, although Novartis said some secondary measures showed signs of clinical activity.

#Biotech #Novartis #RareDisease #ClinicalTrials #Tarsgen

[Tarsgen @Tarsgen]

❤️ Novo Nordisk has stopped two Phase 3 trials of ziltivekimab after an independent review found they were unlikely to deliver a different outcome from the failed ZEUS study.

The drug’s development program is continuing.

#Biotech #NovoNordisk

[Tarsgen @Tarsgen]

🧬 Ivonescimab improved overall survival versus Keytruda in the Phase 3 HARMONi-2 lung cancer trial.

The magnitude of the benefit has not yet been disclosed, and the study was conducted entirely in China.

#Biotech #LungCancer

[Tarsgen @Tarsgen]

💔 Novartis’ pelacarsen failed its pivotal Phase 3 trial, despite substantially lowering Lp(a) levels.

The drug did not significantly reduce the risk of major cardiovascular events compared with placebo.

#Biotech #Novartis #ClinicalTrials

[Tarsgen @Tarsgen]

🧬 Two patients who previously received gene-edited pig kidneys have successfully received human donor kidneys — early evidence that xenotransplantation may help patients spend less time on dialysis while awaiting a donor.

#Biotech #Xenotransplantation

[Tarsgen @Tarsgen]

🧠 The FDA has approved Ionis’ Zanvastro, the first disease-modifying treatment for Alexander disease.

In a pivotal study, treated patients maintained walking speed, while the control group saw a 33% decline.

#Biotech #FDA #RareDisease

[Tarsgen @Tarsgen]

🧬 Novartis has halted autoimmune CAR-T trials after three patient deaths linked to a serious inflammatory complication. BMS has also paused enrollment in separate autoimmune CAR-T studies.

Image: Andrew Hecht / Wikimedia Commons — CC BY 2.0 (cropped & edited)

#Novartis #CART

[Tarsgen @Tarsgen]

🇨🇳 China is rapidly closing the biotech gap.

85% of U.S. biotech and academic leaders surveyed expect America could lose its biomedical leadership within the next decade if current trends continue.

#Biotech #China #LifeSciences

[Tarsgen @Tarsgen]

FDA approves Mimrylo (rusfertide), a new treatment for polycythemia vera. In Phase 3, 76.9% of patients avoided phlebotomy vs. 32.9% on placebo.

Image: NCI — Public Domain (colorized/edited)

#Biotech #FDA #Hematology

[Tarsgen @Tarsgen]

BioNTech halts a Phase 2 personalized mRNA cancer vaccine trial in colorectal cancer.

Image: Ed Uthman / CC BY 2.0 (edited)

#Biotech #mRNA #Oncology

[Tarsgen @Tarsgen]

FDA approves Revolution Medicines’ RasOnque (daraxonrasib) for previously treated metastatic pancreatic cancer. Phase 3 median survival: 13.2 months vs. 6.7 with chemotherapy.

Image: Ed Uthman / CC BY 2.0 (edited)

#Biotech #Oncology #PancreaticCancer

[Tarsgen @Tarsgen]

Moderna and Merck’s personalized mRNA cancer vaccine uses an algorithm to analyze each patient’s tumor and select 34 neoantigens.

Intismeran recently succeeded in a Phase 3 melanoma study. Detailed results have not yet been presented.

Image: NIH/NCI — Public Domain

[Tarsgen @Tarsgen]

Image credit: ZEISS Microscopy — CC BY 2.0. Cropped and edited.
Source: Wikimedia Commons⁠📷

[Tarsgen @Tarsgen]

SK Biopharma is making a $795M bet on epilepsy.

The company secured global rights to Biohaven’s opakalim (BHV-7000), now in Phase 2/3 trials for focal epilepsy. The deal includes $350M upfront and could reach $795M in total.